Cargando…

Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment

BACKGROUND & AIM: We performed lipid analyses at the early period of therapy in patients with chronic hepatitis C who underwent interferon (IFN)-free direct-acting antiviral (DAA) treatment, and we attempted to identify the factors that contributed to a rapid increase in the patients’ serum low-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Satoru, Yatsuhashi, Hiroshi, Abiru, Seigo, Yamasaki, Kazumi, Komori, Atsumasa, Nagaoka, Shinya, Saeki, Akira, Uchida, Shinjiro, Bekki, Shigemune, Kugiyama, Yuki, Nagata, Kazuyoshi, Nakamura, Minoru, Migita, Kiyoshi, Nakao, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040437/
https://www.ncbi.nlm.nih.gov/pubmed/27680885
http://dx.doi.org/10.1371/journal.pone.0163644
_version_ 1782456236384452608
author Hashimoto, Satoru
Yatsuhashi, Hiroshi
Abiru, Seigo
Yamasaki, Kazumi
Komori, Atsumasa
Nagaoka, Shinya
Saeki, Akira
Uchida, Shinjiro
Bekki, Shigemune
Kugiyama, Yuki
Nagata, Kazuyoshi
Nakamura, Minoru
Migita, Kiyoshi
Nakao, Kazuhiko
author_facet Hashimoto, Satoru
Yatsuhashi, Hiroshi
Abiru, Seigo
Yamasaki, Kazumi
Komori, Atsumasa
Nagaoka, Shinya
Saeki, Akira
Uchida, Shinjiro
Bekki, Shigemune
Kugiyama, Yuki
Nagata, Kazuyoshi
Nakamura, Minoru
Migita, Kiyoshi
Nakao, Kazuhiko
author_sort Hashimoto, Satoru
collection PubMed
description BACKGROUND & AIM: We performed lipid analyses at the early period of therapy in patients with chronic hepatitis C who underwent interferon (IFN)-free direct-acting antiviral (DAA) treatment, and we attempted to identify the factors that contributed to a rapid increase in the patients’ serum low-density lipoprotein cholesterol (LDL-C) concentration. METHODS: We retrospectively analyzed the cases of 100 consecutive patients with HCV infection treated at the National Hospital Organization Nagasaki Medical Center: 24 patients underwent daclatasvir (DCV) and asunaprevir (ASV) combination therapy (DCV/ASV) for 24 weeks, and the other 76 patients underwent ledipasvir and sofosbuvir combination therapy (LDV/SOF) for 12 weeks. ΔLDL-C was defined as the changed in LDL-C level at 28 days from the start of therapy. To determine whether ΔLDL-C was associated with several kinds of factors including viral kinetics, we performed a stepwise multiple linear regression analysis. RESULTS: The LDL-C levels in patients treated with LDV/SOF were markedly and significantly elevated (87.45 to 122.5 mg/dl; p<10(−10)) compared to those in the DCV/ASV-treated patients (80.15 to 87.8 mg/dl; p = 0.0056). The median levels of ΔLDL-C in the LDV/SOF and DCV/ASV groups were 33.2 and 13.1, respectively. LDV/SOF combination therapy as an IFN-free regimen (p<0.001) and ΔHCV core antigen (0–1 day drop) (p<0.044) were identified as independent factors that were closely related to the ΔLDL-C. CONCLUSIONS: A rapid increase in the serum LDL-C concentration during the IFN-free treatment of hepatitis C was associated with the type of HCV therapy and a decline of HCV core protein.
format Online
Article
Text
id pubmed-5040437
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50404372016-10-27 Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment Hashimoto, Satoru Yatsuhashi, Hiroshi Abiru, Seigo Yamasaki, Kazumi Komori, Atsumasa Nagaoka, Shinya Saeki, Akira Uchida, Shinjiro Bekki, Shigemune Kugiyama, Yuki Nagata, Kazuyoshi Nakamura, Minoru Migita, Kiyoshi Nakao, Kazuhiko PLoS One Research Article BACKGROUND & AIM: We performed lipid analyses at the early period of therapy in patients with chronic hepatitis C who underwent interferon (IFN)-free direct-acting antiviral (DAA) treatment, and we attempted to identify the factors that contributed to a rapid increase in the patients’ serum low-density lipoprotein cholesterol (LDL-C) concentration. METHODS: We retrospectively analyzed the cases of 100 consecutive patients with HCV infection treated at the National Hospital Organization Nagasaki Medical Center: 24 patients underwent daclatasvir (DCV) and asunaprevir (ASV) combination therapy (DCV/ASV) for 24 weeks, and the other 76 patients underwent ledipasvir and sofosbuvir combination therapy (LDV/SOF) for 12 weeks. ΔLDL-C was defined as the changed in LDL-C level at 28 days from the start of therapy. To determine whether ΔLDL-C was associated with several kinds of factors including viral kinetics, we performed a stepwise multiple linear regression analysis. RESULTS: The LDL-C levels in patients treated with LDV/SOF were markedly and significantly elevated (87.45 to 122.5 mg/dl; p<10(−10)) compared to those in the DCV/ASV-treated patients (80.15 to 87.8 mg/dl; p = 0.0056). The median levels of ΔLDL-C in the LDV/SOF and DCV/ASV groups were 33.2 and 13.1, respectively. LDV/SOF combination therapy as an IFN-free regimen (p<0.001) and ΔHCV core antigen (0–1 day drop) (p<0.044) were identified as independent factors that were closely related to the ΔLDL-C. CONCLUSIONS: A rapid increase in the serum LDL-C concentration during the IFN-free treatment of hepatitis C was associated with the type of HCV therapy and a decline of HCV core protein. Public Library of Science 2016-09-28 /pmc/articles/PMC5040437/ /pubmed/27680885 http://dx.doi.org/10.1371/journal.pone.0163644 Text en © 2016 Hashimoto et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hashimoto, Satoru
Yatsuhashi, Hiroshi
Abiru, Seigo
Yamasaki, Kazumi
Komori, Atsumasa
Nagaoka, Shinya
Saeki, Akira
Uchida, Shinjiro
Bekki, Shigemune
Kugiyama, Yuki
Nagata, Kazuyoshi
Nakamura, Minoru
Migita, Kiyoshi
Nakao, Kazuhiko
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title_full Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title_fullStr Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title_full_unstemmed Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title_short Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
title_sort rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis c interferon-free treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040437/
https://www.ncbi.nlm.nih.gov/pubmed/27680885
http://dx.doi.org/10.1371/journal.pone.0163644
work_keys_str_mv AT hashimotosatoru rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT yatsuhashihiroshi rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT abiruseigo rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT yamasakikazumi rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT komoriatsumasa rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT nagaokashinya rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT saekiakira rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT uchidashinjiro rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT bekkishigemune rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT kugiyamayuki rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT nagatakazuyoshi rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT nakamuraminoru rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT migitakiyoshi rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment
AT nakaokazuhiko rapidincreaseinserumlowdensitylipoproteincholesterolconcentrationduringhepatitiscinterferonfreetreatment